NorthWest Biotherapeutics Inc (NWBO)

[GermanCol]

I completely disagree that the 35 patient group encompassed any DCVax-l recipients.

Instead, JTM 2018

Because of the cross-over trial design, nearly 90% of the ITT population received DCVax-L.



Note: 331 - 35 = 296

296/331= 89.4%

Or “nearly 90%”

Note:

If 2 of the 35 received DCvax, then 33 in the trial didn't receive it, so:

331 - 33 = 298
298/331 = 90%

If 4 of the 35 received DCvax, then 31 in the trial didn't receive it, so:

331 - 31 = 300
300/331 = 90.6%

If 6 of the 35 received DCvax, then 29 in the trial didn't receive it, so:

331 - 29 = 302
302/331 = 91.2%

And so on.

All "nearly 90%". Actually one is exactly 90%.

You can disagree, but I guess this is not the best argument for your disagreement.

For me there is a possibility that some of the 35 patients received DCVax, but were not part of the rGBM arm for the reasons I have explained in other posts. But if it didn't happen, I can sleep well. It doesn't change what I think about the trial results.